Business Description
Blueprint Medicines Corp
NAICS : 325412
SIC : 2834
ISIN : US09627Y1091
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.14 | |||||
Equity-to-Asset | 0.12 | |||||
Debt-to-Equity | 2.55 | |||||
Debt-to-EBITDA | -0.7 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 0.01 | |||||
Beneish M-Score | -2.91 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -33.7 | |||||
3-Year Book Growth Rate | -56.2 | |||||
Future 3-5Y Total Revenue Growth Rate | 49.73 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 66.27 | |||||
9-Day RSI | 57.97 | |||||
14-Day RSI | 54.99 | |||||
6-1 Month Momentum % | 88.28 | |||||
12-1 Month Momentum % | 81.14 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.76 | |||||
Quick Ratio | 3.66 | |||||
Cash Ratio | 3.31 | |||||
Days Inventory | 871.16 | |||||
Days Sales Outstanding | 50.46 | |||||
Days Payable | 273.06 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.9 | |||||
Shareholder Yield % | -1.95 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 96.58 | |||||
Operating Margin % | -193.29 | |||||
Net Margin % | -203.3 | |||||
FCF Margin % | -181.61 | |||||
ROE % | -161.12 | |||||
ROA % | -43.47 | |||||
ROIC % | -120.6 | |||||
ROC (Joel Greenblatt) % | -424.32 | |||||
ROCE % | -49.82 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 21.68 | |||||
PB Ratio | 41.81 | |||||
Price-to-Tangible-Book | 41.81 | |||||
EV-to-EBIT | -10.46 | |||||
EV-to-EBITDA | -10.72 | |||||
EV-to-Revenue | 20.45 | |||||
EV-to-Forward-Revenue | 13.18 | |||||
EV-to-FCF | -11.65 | |||||
Earnings Yield (Greenblatt) % | -9.56 | |||||
FCF Yield % | -8.27 |